JP2015531396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531396A5 JP2015531396A5 JP2015535741A JP2015535741A JP2015531396A5 JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5 JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antibody
- subject
- mabp1
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709741P | 2012-10-04 | 2012-10-04 | |
| US61/709,741 | 2012-10-04 | ||
| PCT/US2013/062899 WO2014055541A1 (en) | 2012-10-04 | 2013-10-01 | Treatment of psychiatric conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020090717A Division JP2020143133A (ja) | 2012-10-04 | 2020-05-25 | 精神障害の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531396A JP2015531396A (ja) | 2015-11-02 |
| JP2015531396A5 true JP2015531396A5 (enExample) | 2016-11-17 |
| JP6750941B2 JP6750941B2 (ja) | 2020-09-02 |
Family
ID=50435375
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535741A Active JP6750941B2 (ja) | 2012-10-04 | 2013-10-01 | 精神障害の治療 |
| JP2020090717A Pending JP2020143133A (ja) | 2012-10-04 | 2020-05-25 | 精神障害の治療 |
| JP2022144756A Withdrawn JP2022177132A (ja) | 2012-10-04 | 2022-09-12 | 精神障害の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020090717A Pending JP2020143133A (ja) | 2012-10-04 | 2020-05-25 | 精神障害の治療 |
| JP2022144756A Withdrawn JP2022177132A (ja) | 2012-10-04 | 2022-09-12 | 精神障害の治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2903643A4 (enExample) |
| JP (3) | JP6750941B2 (enExample) |
| KR (1) | KR20150064091A (enExample) |
| CN (1) | CN104684581A (enExample) |
| AU (1) | AU2013327498B2 (enExample) |
| CA (1) | CA2886757C (enExample) |
| WO (1) | WO2014055541A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102946904A (zh) | 2010-06-18 | 2013-02-27 | 埃克斯生物科技公司 | 关节炎治疗 |
| PH12013500316A1 (en) | 2010-08-23 | 2016-09-02 | Janssen Biotech Inc | Treatment for neoplastic diseases |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| PT2750709T (pt) | 2011-09-23 | 2018-11-22 | Xbiotech Inc | Tratamento da caquexia |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| JP7145162B2 (ja) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク，インコーポレイテッド | 化膿性汗腺炎の処置 |
| CA3095675A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095676A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095740A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin alpha (il-1a) |
| CA3095679A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleuken 1 alpha (il-1a) |
| JPWO2024095677A1 (enExample) | 2022-11-04 | 2024-05-10 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9405021D0 (en) * | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| US5455234A (en) * | 1994-03-16 | 1995-10-03 | Ahluwalia; Gurpreet S. | Inhibition of hair growth |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| HUE029003T2 (en) * | 2008-05-30 | 2017-01-30 | Xbiotech Inc | IL-1 alpha antibodies |
| NZ593905A (en) * | 2009-01-29 | 2013-03-28 | Abbott Lab | Il-1 binding proteins |
| EP2694107B1 (en) * | 2011-04-01 | 2018-08-22 | XBiotech, Inc | Treatment for dermatological pathologies |
| US9724409B2 (en) * | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
-
2013
- 2013-10-01 JP JP2015535741A patent/JP6750941B2/ja active Active
- 2013-10-01 WO PCT/US2013/062899 patent/WO2014055541A1/en not_active Ceased
- 2013-10-01 CA CA2886757A patent/CA2886757C/en active Active
- 2013-10-01 CN CN201380050428.0A patent/CN104684581A/zh active Pending
- 2013-10-01 KR KR1020157009988A patent/KR20150064091A/ko not_active Ceased
- 2013-10-01 EP EP13843079.8A patent/EP2903643A4/en not_active Withdrawn
- 2013-10-01 AU AU2013327498A patent/AU2013327498B2/en not_active Ceased
-
2020
- 2020-05-25 JP JP2020090717A patent/JP2020143133A/ja active Pending
-
2022
- 2022-09-12 JP JP2022144756A patent/JP2022177132A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509662A5 (enExample) | ||
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| IL240179A0 (en) | Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood | |
| JP2015530399A5 (enExample) | ||
| PH12014501685A1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
| IL236664A0 (en) | Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease | |
| IL212633A (en) | A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs | |
| SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| HUE043540T2 (hu) | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben | |
| MX2019014658A (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina. | |
| LT2013015A (lt) | Farmacinės kompozicijos | |
| BR112013002167A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação | |
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| MX356808B (es) | Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. | |
| JP2014526559A5 (enExample) | ||
| JP2015531397A5 (enExample) | ||
| JP2012512814A5 (enExample) | ||
| EP2703488A4 (en) | COMPOSITION TO PREDICT SENSITIVITY TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS AND METHODS THEREFOR | |
| EP2991681A4 (en) | TOPICAL COMPOSITION AND CARRIER FOR THE ADMINISTRATION OF PHARMACEUTICAL OR COSMETIC ACTIVE SUBSTANCES | |
| WO2014185908A3 (en) | Hybridoma clones, monoclonal antibodies, and methods of use | |
| JP2012512815A5 (enExample) |